Role of race in the pharmacotherapy of heart failure. - Wikidata - awgldk - TriplyDB

Role of race in the pharmacotherapy of heart failure.

Role of race in the pharmacotherapy of heart failure.

http://www.wikidata.org/entity/Q34564305

about

Efficacy of tiotropium inhalation powder in african-american patients with chronic obstructive pulmonary disease.

P2860

Q46498379-CB7BC557-1C6D-4A21-BF1B-CE58BE9148FF

P2860

Role of race in the pharmacotherapy of heart failure.

http://www.wikidata.org/entity/Q34564305

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Role of race in the pharmacotherapy of heart failure.

@ast

Role of race in the pharmacotherapy of heart failure.

@en

Role of race in the pharmacotherapy of heart failure.

@nl

type

label

Role of race in the pharmacotherapy of heart failure.

@ast

Role of race in the pharmacotherapy of heart failure.

@en

Role of race in the pharmacotherapy of heart failure.

@nl

prefLabel

Role of race in the pharmacotherapy of heart failure.

@ast

Role of race in the pharmacotherapy of heart failure.

@en

Role of race in the pharmacotherapy of heart failure.

@nl

P1433

Q34564305-FA011A6D-7511-4774-BD75-E0C9FE6D7ED4

P1476

Q34564305-A1E6E7DC-937F-47D4-A17A-E7598ACF5017

P2093

Q34564305-4C0FDD22-03F6-4B65-9FC6-0918F4C35F53

Q34564305-5C950237-72B1-42AB-B08F-EA14B29C7FE4

P2860

Q34564305-052B133A-6427-4A34-8C27-BE7B10F3FA38

Q34564305-0BC9438C-52E6-4693-9EB4-50FE45A39C21

Q34564305-16DD0C3A-B973-4C9E-B5B7-2B29EE10FBB5

Q34564305-2F54AFE6-EC40-4B4A-B8BF-3649D63AB5A7

Q34564305-41CF8001-2B92-42EE-8A41-156915A88977

Q34564305-492E023F-8CD3-49BB-96E6-6608DA96DF1D

Q34564305-4DF6786B-DCFB-4C2C-B3A8-FD437D4843BC

Q34564305-4FE62D5B-0F5E-4B81-BF0B-AB6EE9EE9E62

Q34564305-555B9CF3-CB5E-4BE2-801E-5E2A689248FF

Q34564305-722F465D-A3FF-4AA6-8725-F3BFE4C3BB58

P304

Q34564305-1400A680-1B81-4F7D-B40D-24B1BE3BAC5D

P31

Q34564305-9FFFB4AE-7FD4-44D9-B54D-9A20995012A2

P356

Q34564305-61D27565-4205-45D0-8894-DB6DDCBD3AD9

P407

Q34564305-68B0F6DD-4C5B-479B-9A2C-1921091C10DA

P433

Q34564305-D663C538-9249-4348-A2F5-DCAD1EFBEE5F

P478

Q34564305-6B4D1E56-0CC2-4C78-A349-A13BABEECADE

P577

Q34564305-5D53BE17-7DB7-42AB-904F-2A39EB1FF655

P5875

Q34564305-E2359C59-0F0A-4125-AD1B-89AB15D8823E

P698

Q34564305-F80736DB-D6B8-47A6-9C90-57F34BEDCAE8

P921

Q34564305-99D7C17C-AC6C-498B-84F3-047B92EE4026

P356

P1433

Annals of Pharmacotherapy

P1476

Role of race in the pharmacotherapy of heart failure.

@en

P2093

James S Kalus

http://www.w3.org/2001/XMLSchema#string

Jean M Nappi

http://www.w3.org/2001/XMLSchema#string

P2860

Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group

Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

The pharmacology of carvedilol.

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Racial differences in cardiac structure and function in essential hypertension

The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure.

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.

P304

471-478

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1A166

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11468576

http://www.w3.org/2001/XMLSchema#string

P698

11895062

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy